06/26/2026
Scientists at The Wistar Institute have developed an innovative single-dose DNA delivery method that could revolutionize how we treat type 2 diabetes and obesity.
Currently, popular incretin-mimicking drugs like Ozempic and Wegovy require weekly injections or daily pills because they break down quickly in the body. This creates hurdles for patient access and long-term compliance, often leading to a rebound in weight gain and blood glucose issues once treatment stops.
Led by Dr. Ebony Gary, a research assistant professor in the laboratory of Dr. David B. Weiner, Wistar researchers engineered DNA instructions that appears to prompt a patient’s own cells to continuously produce these therapeutic proteins. In preclinical models, a single dose of this DNA construct produced metabolic improvements and sustained weight loss for up to 70 days, lasting up to 10 times longer than current therapies.
Read more about this breakthrough and where the science is headed: https://bit.ly/4oL7w1C